The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice

International Immunopharmacology

Volumn 10, Issue 10, 2010, Pages 1310-1315

  Kim, Tae Ho ^a   Jung, Jung A ^a   Kim, Gun Dong ^a   Jang, An Hee ^a   Cho, Jeong Je ^a   Park, Yong Seek ^a   Park, Cheung Seog ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

2,4 dinitrofluorobenzene (DNFB); Atopic dermatitis; CD4+ T cells; NC Nga; Trichostatin A

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 4; TRICHOSTATIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED STRAINS;

EID: 77957230935     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.08.004     Document Type: Article

References (32)

1. Leung D.Y., Bieber T. Atopic dermatitis. Lancet 2003, 361:151-160.
2. Shiohara T., Hayakawa J., Mizukawa Y. Animal models for atopic dermatitis: are they relevant to human disease?. J Dermatol Sci 2004, 36:1-9.
3. Miyauchi-Hashimoto H., Okamoto H., Sugihara A., Horio T. Therapeutic and prophylactic effects of PUVA photochemotherapy on atopic dermatitis-like lesions in NC/Nga mice. Photodermatol Photoimmunol Photomed 2005, 21:125-130.
4. Lee S.J., Oh S.G., Seo S.W., Ahn H.J., Geum D., Cho J.J., et al. Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/Nga mice. Biol Pharm Bull 2007, 30:1468-1471.
5. Tomimori Y., Tanaka Y., Goto M., Fukuda Y. Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition. J Invest Dermatol 2005, 124:119-124.
6. Takeshita K., Yamasaki T., Akira S., Gantner F., Bacon K.B. Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse. Int Immunol 2004, 16:685-695.
7. Kim Y.-J., Ryu J.-C. Evaluation of the genetic toxicity of synthetic chemical (XVII) - in vitro mouse lymphoma assay and in vitro supravital micronucleus assay with 1, 2-dichlorobenzene. Mol Cell Toxicol 2007, 3:113-118.
8. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
9. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92:1210-1216.
10. Timmermann S., Lehrmann H., Polesskaya A., Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001, 58:728-736.
11. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
12. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003, 111:539-552.
13. Chung Y.L., Lee M.Y., Wang A.J., Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717.
14. Nishida K., Komiyama T., Miyazawa S., Shen Z.N., Furumatsu T., Doi H., et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004, 50:3365-3376.
15. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990, 265:17174-17179.
16. Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 1976, 29(1):1-6.
17. Lam A.L., Pazin D.E., Sullivan B.A. Control of gene expression and assembly of chromosomal subdomains by chromatin regulators with antagonistic functions. Chromosoma 2005, 114:242-251.
18. Choi J.H., Oh S.W., Kang M.S., Kwon H.J., Oh G.T., Kim D.Y. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005, 35:89-96.
19. + T cell responses. BMC Cancer 2003, 3:30.
20. Oranje A.P., Glazenburg E.J., Wolkerstorfer A., de Waard-van der Spek F.B. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007, 157:645-648.
21. Kim T.H., Jung J.A., Kim G.D., Jang A.H., Ahn H.J., Park Y.S., et al. Melatonin inhibits the development of 2, 4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. J Pineal Res 2009, 47:324-329.
22. Singh V.K., Mehrotra S., Agarwal S.S. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999, 20:147-161.
23. + bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 2008, 17:34-39.
24. Wahl S.M., Chen W. Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res Ther 2005, 7:62-68.
25. Wenzel J., Henze S., Brahler S., Bieber T., Tuting T. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol 2005, 14:454-459.
26. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
27. Gray S.G., Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006, 1:67-75.
28. Gray S.G., Ekstrom T.J. The human histone deacetylase family. Exp Cell Res 2001, 262:75-83.
29. Gray S.G., Teh B.T. Histone acetylation/deacetylation and cancer: an "open" and "shut" case?. Curr Mol Med 2001, 1:401-429.
30. Reilly C.M., Thomas M., Gogal R., Olgun S., Santo A., Sodhi R., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 2008, 31:123-130.
31. Elaut G., Laus G., Alexandre E., Richert L., Bachellier P., Tourwe D., et al. A metabolic screening study of trichostatin A (TSA) and TSA-like histone deacetylase inhibitors in rat and human primary hepatocyte cultures. J Pharmacol Exp Ther 2007, 321:400-408.
32. Deane J.A., Hickey M.J. Molecular mechanisms of leukocyte trafficking in T-cell-mediated skin inflammation: insights from intravital imaging. Expert Rev Mol Med 2009, 11:e25.